Oncology

Latest News

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Patient navigation | Image credit: AON
With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance Period

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Antiangiogenic Therapy in NSCLC
July 18th 2018

Antiangiogenic Therapy in NSCLC

Breakthroughs in Treating NSCLC
July 18th 2018

Breakthroughs in Treating NSCLC

Key Points From the REVEL Trial in NSCLC
July 18th 2018

Key Points From the REVEL Trial in NSCLC

Considerations for Antiangiogenic Therapy in NSCLC
July 18th 2018

Considerations for Antiangiogenic Therapy in NSCLC

Evidence for Immunotherapy in Frontline NSCLC
July 18th 2018

Evidence for Immunotherapy in Frontline NSCLC

Future Use of Antiangiogenic Agents in NSCLC
July 18th 2018

Future Use of Antiangiogenic Agents in NSCLC

Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC
July 18th 2018

Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC

VEGF Inhibition in NSCLC
July 18th 2018

VEGF Inhibition in NSCLC

The Phase 3 REVEL Trial in NSCLC
July 18th 2018

The Phase 3 REVEL Trial in NSCLC

Ramucirumab in Relapsed/Refractory NSCLC
July 18th 2018

Ramucirumab in Relapsed/Refractory NSCLC

Bevacizumab in NSCLC
July 18th 2018

Bevacizumab in NSCLC

Significance of KEYNOTE-189 in NSCLC
July 18th 2018

Significance of KEYNOTE-189 in NSCLC

Site Logo
July 18th 2018

Robotic Surgery Complements Chemotherapy, Safer Than Radiation, in Oral Cancer

Surabhi Dangi-Garimella, PhD
Results presented at the 2018 American Society of Clinical Oncology's Annual Meeting found that transoral robotic-assisted surgery (TORS), following chemotherapy and neck resections, is an effective model for the definitive treatment for oropharyngeal squamous cell carcinoma (OPSCC) while avoiding the adverse effects of radiation.
Site of Chemotherapy Administration Impacts Spending: An Interview With Yamini Kalidindi
July 17th 2018

Site of Chemotherapy Administration Impacts Spending: An Interview With Yamini Kalidindi

There are concerns that cancer care costs may increase as the site of provider-administered cancer drugs shifts from physician offices to hospital outpatient departments. The lead author of a July paper explains why the findings of her study differ from previous research and highlights the importance of considering patient characteristics.
Study Finds Panel of Circulating Protein Biomarkers Improve Lung Cancer Risk Assessment
July 17th 2018

Study Finds Panel of Circulating Protein Biomarkers Improve Lung Cancer Risk Assessment

Alison Rodriguez
Current screening criteria for lung cancer risk assessments often miss a large proportion of cases. Research suggests that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
From Patient Advocates to Pharma, Groups Weigh in on Trump Blueprint for Drug Costs
July 17th 2018

From Patient Advocates to Pharma, Groups Weigh in on Trump Blueprint for Drug Costs

Mary Caffrey
Interest groups representing drug companies, patients, providers, and health plans all submitted comments to a Request for Information on the Trump administration blueprint for controlling drug prices and out-of-pocket costs.
Quizartinib Effective in Patients With FLT3-ITD–Positive Relapsed, Refractory AML
July 17th 2018

Quizartinib Effective in Patients With FLT3-ITD–Positive Relapsed, Refractory AML

David Bai
A phase 2 trial evaluated the safety and efficacy of quizartinib in patients with relapsed/refractory acute myeloid leukemia (AML), compared with salvage chemotherapy.
Podcast: This Week in Managed Care&mdash;Trump Administration Continues to Unravel the ACA and Other Health News
July 14th 2018

Podcast: This Week in Managed Care&mdash;Trump Administration Continues to Unravel the ACA and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: July 13, 2018
July 13th 2018

This Week in Managed Care: July 13, 2018

This week, the top managed care stories included additional moves by the Trump administration to unravel the Affordable Care Act; Pfizer canceled a round of drug price increases after speaking to the president; advocates for 340B sound the alarm on efforts to reform the program.
Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers
July 12th 2018

Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers

Samantha DiGrande
Yesterday, drug manufacturer Bristol-Myers Squibb announced that the FDA has approved the combination nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following a fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy treatment.
Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission
July 12th 2018

Characteristics of Patients With CML Willing to Attempt Treatment-Free Remission

Laura Joszt, MA
Only 34% of patients with chronic myeloid leukemia (CML) in a small study in China were likely to be positive about attempting treatment-free remission.
Study Identifies New Form of Small-Cell Lung Cancer
July 12th 2018

Study Identifies New Form of Small-Cell Lung Cancer

Alison Rodriguez
Researchers have recently discovered a new type of small-cell lung cancer, and the discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.
FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer
July 11th 2018

FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer

Samantha DiGrande
The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).
CLL: Combination Strategies and Unmet Needs
July 11th 2018

CLL: Combination Strategies and Unmet Needs

CLL: Rationale for Ibrutinib and Sequencing
July 11th 2018

CLL: Rationale for Ibrutinib and Sequencing

Initiating Frontline Therapy in CLL
July 11th 2018

Initiating Frontline Therapy in CLL

The Biology and Diagnosis of CLL
July 11th 2018

The Biology and Diagnosis of CLL

Combination Therapy Values and Future Outlook in CLL
July 11th 2018

Combination Therapy Values and Future Outlook in CLL

CLL: Impact of Combination Therapies on Managed Care
July 11th 2018

CLL: Impact of Combination Therapies on Managed Care

Role of Real-World Data and Sequencing in CLL
July 11th 2018

Role of Real-World Data and Sequencing in CLL

<1
...
414243444546474849
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo